PTGX Logo

Protagonist Therapeutics, Inc. (PTGX) 

NASDAQ
Market Cap
$2.47B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
678 of 774
Rank in Industry
367 of 432

Largest Insider Buys in Sector

PTGX Stock Price History Chart

PTGX Stock Performance

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II …

Insider Activity of Protagonist Therapeutics, Inc.

Over the last 12 months, insiders at Protagonist Therapeutics, Inc. have bought $0 and sold $7.39M worth of Protagonist Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Protagonist Therapeutics, Inc. have bought $908,814 and sold $1.89M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 24,000 shares for transaction amount of $160,800 was made by SELICK HAROLD E (director) on 2020‑03‑12.

List of Insider Buy and Sell Transactions, Protagonist Therapeutics, Inc.

2024-11-15SaleChief Medical Officer
1,906
0.0032%
$40.98$78,108-1.12%
2024-09-11SaleChief Financial Officer
14,203
0.0239%
$44.49$631,8720.00%
2024-09-10Saledirector
8,000
0.0136%
$45.00$360,000+2.14%
2024-07-24Saledirector
8,000
0.013%
$40.00$320,0000.00%
2024-06-07SalePresident and CEO
35,000
0.0603%
$35.19$1.23M+21.48%
2024-06-07Saledirector
8,000
0.0137%
$35.00$280,000+21.48%
2024-04-18SaleChief Financial Officer
1,234
0.0021%
$25.11$30,986+53.47%
2024-04-01SalePresident and CEO
25,000
0.0429%
$28.31$707,750+27.33%
2024-03-01SalePresident and CEO
30,000
0.051%
$31.62$948,600+5.63%
2024-03-01SaleChief Financial Officer
14,248
0.0247%
$32.24$459,318+5.63%
2024-03-01Saledirector
12,975
0.0219%
$31.34$406,637+5.63%
2024-02-29SaleChief Financial Officer
9,939
0.0174%
$30.69$305,048+11.86%
2024-01-09SaleChief Development Officer
5,000
0.0084%
$25.00$125,000+20.58%
2023-12-13SalePresident and CEO
75,000
0.1305%
$20.08$1.51M+51.12%
2023-11-15SaleChief Medical Officer
1,848
0.0032%
$16.24$30,012+77.62%
2021-12-21SalePresident and CEO
15,000
0.0311%
$32.14$482,171-70.97%
2021-08-17SaleChief Scientific Officer
14,779
0.0303%
$47.56$702,889-47.52%
2021-02-11Saledirector
3,700
0.0084%
$25.09$92,833+29.81%
2021-02-10Saledirector
4,700
0.011%
$25.47$119,722+32.45%
2021-01-19SalePresident and CEO
24,846
0.0557%
$24.60$611,105+31.22%

Insider Historical Profitability

126.31%
PATEL DINESH V PH DPresident and CEO
515415
0.8648%
$41.53111+243.28%
Gupta SuneelChief Development Officer
187567
0.3147%
$41.5311+243.28%
Papanek Juliedirector
2453255
4.1163%
$41.5310+18.24%
JOHNSON & JOHNSON10 percent owner
2449183
4.1095%
$41.5310+18.24%
CANAAN X L.P.10 percent owner
2116552
3.5514%
$41.53113+18.24%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Farallon Capital$166.03M9.795.74M+0.08%+$131,428.991.17
BlackRock$161.13M9.55.57M+0.46%+$740,116.19<0.01
RTW Investments, LP$153.78M9.065.32M0%+$02.3
Bvf Inc Il$108.66M6.43.76M-34.62%-$57.54M0.8
State Street$94.67M5.583.27M+19.87%+$15.7M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.